Category: molecular cancer therapeutics

Case closed? Fired Pfizer researcher slated for seven retractions

Pfizer has discovered two additional papers that merit retraction from the lab of a former employee. One of the papers, published in Clinical Cancer Research, was retracted earlier this month.

Last year, Pfizer requested retractions of five papers from the lab of breast cancer researcher Min-Jean Yin, who was fired after an investigation revealed image duplication. The papers were first questioned on PubPeer. By April 2017, all five papers had been retracted.

After the initial probe, the pharmaceutical giant conducted a follow-up review of papers originating from Yin’s lab (which Leonid Schneider posted about on May 23). A spokesperson for the company told us that the review revealed two more articles that merited retraction “in light of data integrity issues relating to the figures therein.” The 2013 paper in Clinical Cancer Research was retracted earlier this month at Pfizer’s request. On May 1, 2017, Pfizer asked PLOS ONE to retract a 2013 paper. Continue reading Case closed? Fired Pfizer researcher slated for seven retractions

Former UCLA vice-chancellor loses cancer paper for image manipulation

The former vice chancellor for research at the University of California, Los Angeles, has retracted a 2012 paper after an internal investigation found evidence of image manipulation.

The journal Molecular Cancer Therapeutics received a letter about the problems with the paper from the UCLA Research Integrity Officer, and a retraction request from last author James Economou, also the chief of surgical oncology.

According to the notice, the paper duplicated images from a 2011 paper also by first author Ali Jazirehi, based at UCLA. This is Jazirehi’s second retraction.

Here’s more from the notice:

Continue reading Former UCLA vice-chancellor loses cancer paper for image manipulation

A university asked for numerous retractions. Eight months later, three journals have done nothing.

Anil Jaiswal

When journals learn papers are problematic, how long does it take them to act?

We recently had a chance to find out as part of our continuing coverage of the case of Anil Jaiswal at the University of Maryland, who’s retracted 15 papers (including two new ones we recently identified), and has transitioned out of cancer research. Here’s what happened.

As part of a public records request related to the investigation, we received letters that the University of Maryland sent to 11 journals regarding 26 “compromised” papers co-authored by Jaiswal, four of which had been retracted by the time of the letter. The letters were dated between August and September 2016 (and one in February) — although, in some cases, the journals told us they received the letter later. Since that date, three journals have retracted nine papers and corrected another, waiting between four and six months to take action. One journal published an editorial note of concern within approximately two months after the university letter.

And six journals have not taken any public action.

Continue reading A university asked for numerous retractions. Eight months later, three journals have done nothing.

Cancer researcher in Germany loses multiple papers after misconduct finding

A pathology journal is retracting two papers after an investigation at the last author’s institution in Germany found evidence of scientific misconduct.

The notice for both papers cites an investigation involving Regine Schneider-Stock, who studies cancer biology at the Friedrich Alexander-University Erlangen-Nuremberg (FAU). Meanwhile, another 2005 paper that lists Schneider-Stock as the first author was retracted in October, noting evidence of image manipulation.

The most recent retractions, from the American Journal of Pathology, note that FAU declined to provide the journal with details of its investigation beyond a prepared statement:

Continue reading Cancer researcher in Germany loses multiple papers after misconduct finding

2014 ORI finding results in retraction of cancer paper with manipulated images

Mol Can TherA paper flagged in an Office of Research Integrity notice more than one year ago has finally been retracted. According to the notice, the paper includes images manipulated by author H. Rosie Xing, a former University of Chicago cancer researcher.

The main conclusions of the paper are affected by the ORI finding, according to the retraction note from Molecular Cancer Therapeutics. But otherwise, the note contains information that was available in the ORI finding, published in December 2014.

“Pharmacologic Inactivation of Kinase Suppressor of Ras1 Sensitizes Epidermal Growth Factor Receptor and Oncogenic Ras-Dependent Tumors to Ionizing Radiation Treatment” has been cited seven times, according to Thomson Scientific’s Web of Knowledge — twice since the ORI finding came out.

The retraction note explains which images were affected by the manipulation:

Continue reading 2014 ORI finding results in retraction of cancer paper with manipulated images

Cancer researcher contributed “false data” to 11 studies

ori-logoA former cancer researcher has falsified data in 11 studies, according to the results of a investigation scheduled to be published in the Federal Register tomorrow.

The Office of Research Integrity’s findings are based on an inquiry at Virginia Commonwealth University, where Girija Dasmahapatra worked until July of this year, investigating possible therapies for cancer. The misconduct affected research funded by three grants from the National Institutes of Health. Steven Grant, a researcher at VCU, is the principal investigator on the grants, each of which total over $2 million in funding. All of the 11 affected papers will be corrected or retracted, according to the ORI notice.

Two of the papers containing “falsified and/or fabricated” data — a study on an experimental combination of drugs for blood cancer and one on chemotherapies for rare forms of lymphoma  — were covered in press releases by VCU.

According to the notice in the Federal Register:

Continue reading Cancer researcher contributed “false data” to 11 studies

ORI sanctions former University of Chicago and UCSF scientists for faking findings

H. Rosie Xing
H. Rosie Xing

The stories behind several recent inscrutable retraction notices became a bit more clear today when the Office of Research Integrity (ORI) issued findings in cases involving former researchers at the University of Chicago and the University of California, San Francisco.

The ORI found that H. Rosie Xing, a former assistant professor at the University of Chicago, Continue reading ORI sanctions former University of Chicago and UCSF scientists for faking findings

A “retraction in part” for Anil Potti and colleagues, in Molecular Cancer Therapeutics

A partial retraction has joined the ten retractions and five corrections of Anil Potti’s papers, this one of a 2008 paper in Molecular Cancer Therapeutics. The move comes 14 months after the retraction of the Nature Medicine paper upon which much of the Molecular Cancer Therapeutics paper was based.

Here’s the notice: Continue reading A “retraction in part” for Anil Potti and colleagues, in Molecular Cancer Therapeutics